Becton Dickinson and Company (BDX) - Stock Report

**Fiscal Q2 2026 (reported May 7, 2026; the latest reported quarter as of the June 23, 2026 price date):** Continuing revenue for the quarter was $4.714bn, up 5.2% reported and 2.6% foreign-currency neutral; reported diluted EPS from continuing operations for the quarter was $(0.13) against $2.90 management-adjusted continuing EPS, up 3.9% reported and 1.1% foreign-currency neutral from $2.79. The $3.03 per-share bridge from reported to adjusted EPS is net after tax and dilution; the gross pre-tax add-back categories discussed later are not cash charges one-for-one. Management raised full-year adjusted diluted EPS guidance from continuing operations to $12.52-$12.72 and reaffirmed low-single-digit-plus reported revenue growth for FY2026; the May 7 release gave no separate next-quarter guidance. First-half post-capex cash of $1.095bn fell well short of $2.839bn in dividends and buybacks, so second-half organic cash conversion — not the adjusted guide — is the decisive proof point. The proof burden is that FY2025-style cash conversion remains durable in the New BD portfolio after the Waters separation completed on February 9, 2026 and the $2.0bn ASR was executed in Q2, with debt repayment, tariff pressure, FDA remediation work, low reported ROIC, leverage and product-liability/legal accruals still competing for cash.

The key macro issue is not hospital demand in isolation, but whether procedure-driven volumes and drug-delivery demand pass through FDA remediation, litigation, tariffs, China procurement pressure and leverage into reported earnings and post-capex cash; if they do, BD can look like a discounted medtech cash-conversion repair, but if they do not, adjusted EPS remains a weak selected fair value.

BD completed the spin-off of its former Biosciences and Diagnostic Solutions business and the combination with Waters on February 9, 2026. That matters because the old Life Sciences segment is no longer part of continuing operations; the continuing company is now organized around four segments: Medical Essentials, Connected Care, BioPharma Systems and Interventional.

The fiscal Q2 2026 earnings release recast prior periods on that basis, so the report should be read through continuing operations rather than the old three-segment structure. Medical Essentials supplies the high-volume hospital and lab consumables that make BD hard to displace but also expose it to tariffs, resin/labor costs and China volume-based procurement. Connected Care houses medication management, infusion systems and Advanced Patient Monitoring, so its value bridge depends on system placements, software/service attachment and remediation discipline. BioPharma Systems supplies prefillable and drug-delivery components to pharmaceutical customers, including GLP-1-related injectable-drug delivery demand, but vaccine demand is a current drag. Interventional is the higher-margin procedure tool franchise across peripheral intervention, urology/critical care and surgery.

The value stack the multiple pays for is recurrence: the bulk of revenue is single-use consumables and installed-system pull-through that reorder across the capital cycle rather than one-off equipment sales, with Interventional and BioPharma layering the higher-margin, higher-growth content on top of that base.